Daiichi Sankyo has increased focus on high growth oncology and entered into a potentially very lucrative deal with Merck. We like the company, we like the focus, but the valuation concerns us.
What is covered in the Full Insight:
Overview of Japan's Oncology Market
Transformation of Daiichi Sankyo
Focus on Oncology
Agreements and Partnerships
Earnings Outlook and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.